Repligen Corporation is a life sciences company focused on the development, production, and commercialization of products used in the process of manufacturing biological drugs. The Company's  bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. Repligen is a manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. The Company also supplies several growth factor products used to increase cell culture productivity in biomanufacturing and has developed and marketed a series of OPUS (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. 

Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
236 (est)
Repligen was founded in 1981 and is headquartered in Waltham, US
Report incorrect company information

Repligen Office Locations

Repligen has offices in Waltham and Lund
Waltham, US (HQ)
100 41 Seyon St
Lund, SE
47 Sankt Lars väg
Show all (2)
Report incorrect company information

Repligen Financials and Metrics

Repligen Financials

Repligen's revenue was reported to be $104.54 m in FY, 2016 which is a 25.1% increase from the previous period.
USD

Revenue (Q3, 2017)

36.6 m

Net income (Q3, 2017)

4.7 m

EBIT (Q3, 2017)

(406 k)

Market capitalization (20-Apr-2018)

1.5 b

Cash (30-Sep-2017)

159.7 m
Repligen's current market capitalization is $1.5 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

68.2 m63.5 m83.5 m104.5 m

Revenue growth, %

(7%)31%25%

General and administrative expense

30.9 m

R&D expense

7.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

18.8 m16.3 m15.6 m15.3 m20.8 m21.5 m19.8 m30.6 m32.5 m36.6 m

General and administrative expense

2.9 m3.4 m4.3 m4.5 m6 m6.2 m6 m7 m8.1 m7.1 m9.2 m11.2 m

R&D expense

1.4 m1.2 m1.4 m1.6 m1.6 m1.3 m1.5 m1.5 m1.9 m1.9 m1.7 m1.9 m

Operating expense total

10.8 m11 m12.4 m13.1 m16.8 m16.8 m16.1 m21.6 m23.3 m20.9 m24.9 m27 m37 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

39.8 m35.4 m54.1 m122.2 m

Accounts Receivable

5.3 m

Inventories

1.2 m2.1 m2.1 m24.7 m

Current Assets

86.4 m80.9 m103.3 m184.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

42.2 m49.2 m33.8 m35.9 m31.2 m40 m48.1 m53.2 m172.6 m157.7 m129.7 m142.2 m159.7 m

Accounts Receivable

394.4 k523.4 k57 k331 k564 k226 k669 k534 k598 k

Inventories

10.1 m11.4 m12.8 m13.3 m12.2 m14.3 m15.9 m21.3 m23.2 m24.5 m24 m26.1 m38.7 m

Current Assets

87.4 m88.7 m73.9 m75.7 m83.5 m93.3 m96.3 m105.2 m217.9 m219.8 m185.8 m195.9 m231.2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(1.6 m)8.2 m9.3 m11.7 m

Depreciation and Amortization

1.3 m4 m4.6 m5.3 m

Inventories

(870.3 k)(860.1 k)(6.1 m)(6.2 m)

Accounts Payable

247.2 k2.3 m3 m(1.8 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Net Income

5.9 m4.3 m2.8 m1.5 m2.9 m3.6 m2.5 m1.6 m5.5 m6.7 m3.1 m4.7 m

Depreciation and Amortization

1.2 m2.5 m3.8 m

Inventories

12.8 m13.3 m12.2 m14.3 m15.9 m(3.1 m)(5.1 m)(6.5 m)24 m38.7 m

Accounts Payable

3.9 m2.8 m4.1 m4.3 m3 m(1.6 m)511 k(1.9 m)4.6 m6.4 m
USDY, 2017

Revenue/Employee

155 k

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

Repligen News and Updates

BRIEF-Repligen prices public offering of shares of common stock

* Repligen Corporation prices public offering of shares of common stock
Report incorrect company information